Table 1 Patient characteristics
Patient characteristics | Total number n=81 (%) | Matched n=22 (%) | Non-matched n=59 (%) | P value (matched vs. non-matched) |
|---|---|---|---|---|
Median age, years (range) | 54 (22-74) | 54 (37-74) | 54 (22-73) | / |
Sex | ||||
 Female | 37 (45.7%) | 11 (50%) | 26 (44.1%) | 0.6 |
 Male | 44 (54.3%) | 11 (50%) | 33 (55.95) |  |
Smoking status | ||||
 Never | 61 (75.3%) | 18 (81.8%) | 43 (72.9%) | 0.4 |
 Former | 20 (24.7%) | 4 (18.2%) | 16 (27.1%) |  |
Histology type | ||||
 Adenocarcinoma | 79 (97.5%) | 22 (100%) | 57 (96.6%) | 1.0 |
 Adenosquamous | 2 (2.5%) | 0 | 2 (3.4%) |  |
EGFR mutation status | ||||
 19DEL | 39 (48.1%) | 13 (59.1%) | 26 (44.1%) | 0.2 |
 21L858R | 34 (42.0%) | 9 (40.9%) | 25 (42.4%) |  |
 Others* | 8 (9.9%) | 0 | 8 (13.5%) | |
Concurrent brain metastases | ||||
 Yes | 59 (72.8%) | 13 (59.1%) | 46 (78%) | 0.09 |
 No | 22 (27.2%) | 9 (40.9%) | 13 (22%) |  |
No. of extracranial metastases | ||||
 0–1 | 48 (59.3%) | 15 (68.2%) | 33 (55.9%) | 0.3 |
 ≥2 | 33 (40.7%) | 7 (31.8%) | 26 (44.1%) |  |
ECOG-PS | ||||
 0–1 | 44 (54.3%) | 11 (50%) | 33 (55.9%) | 0.6 |
 ≥2 | 37 (45.7%) | 11 (50%) | 26 (44.1%) |  |
No. of prior systemic therapies | 3 (1-7) | 2 (1-7) | 2 (1-4) | 0.4 |
Prior brain radiotherapy | ||||
 Yes | 25 (30.9%) | 6 (27.3%) | 19 (32.2%) | 0.7 |
 No | 56 (69.1%) | 16 (72.7%) | 40 (67.8%) |  |
LM status | ||||
 PD on pre-existing LM | 49 (60.5%) | 11 (50%) | 38 (64.4%) | 0.2 |
 First diagnosis of LM | 32 (39.5%) | 11 (50%) | 21 (35.6%) |  |
Progression mode on osimertinib | ||||
 CNS-only progression | 67 (82.7%) | 18 (81.8%) | 49 (83.1%) | 1.0 |
 Systemic progression | 14 (17.3%) | 4 (18.2%) | 10 (16.9%) |  |